Estrella Immunopharma IncNASDAQ:ESLA
- LAST PRICE1.0400
- TODAY'S CHANGE (%)0.0400 (4.0000%)
- Bid / Lots0.9500/ 50
- Ask / Lots1.0400/ 2
- Open / Previous Close1.0198 / 1.0000
- Day Range
- 52 Week Range
- Volume10,355
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ESLA |
|---|---|---|
| 09:37 ET | 8289 | 1.05 |
| 09:48 ET | 814 | 1.05 |
| 10:02 ET | 120 | 1.05 |
| 10:04 ET | 400 | 1.05 |
| 10:15 ET | 450 | 1.04 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Estrella Immunopharma Inc | 32.9M | -4.4x | --- |
Lantern Pharma Inc | 33.2M | -1.8x | --- |
Grace Therapeutics, Inc | 33.3M | -3.1x | --- |
NextCure Inc | 33.3M | -0.6x | --- |
CERo Therapeutics Holdings Inc | 32.2M | -0.4x | --- |
ProMIS Neurosciences Inc | 33.7M | -5.0x | --- |
Company Information
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
Contact Information
- Headquarters
- 5858 Horton Street, Suite 370EMERYVILLE, CA, United States 94608
- Phone
- 510-318-9098
- Fax
- 847-827-5303
Executives
- Chairman of the Board
- Hong Zhang
- Chief Executive Officer, Director
- Cheng Liu
- Chief Financial Officer, Company Secretary
- Luqi Wen
- Director
- Marsha Roberts
- Director
- Fan Wu
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.24 |
Book Value | $0.12 |
P/E Ratio | -4.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
